Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab

NCT01213329 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant

Interventions

DRUG: Alemtuzumab

Sponsor

Northwestern University

Collaborators

[object Object]